Kyle Mikson CFA, an analyst from Canaccord Genuity, reiterated the Buy rating on Oxford Nanopore Technologies PLC. The associated price target remains the same with p180.00.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Kyle Mikson CFA has given his Buy rating due to a combination of factors that highlight Oxford Nanopore Technologies PLC’s strong market performance and growth potential. The company’s impressive first-half performance in 2025 was primarily driven by the robust adoption of its PromethION product range, which significantly boosted research revenue in regions like EMEA and APAC, despite a slight decline in AMR. This growth in research revenue, along with a strong performance in the Applied markets, particularly in Clinical and BioPharma sectors, underscores the company’s strategic execution and long-term growth prospects.
Moreover, Oxford Nanopore Technologies has reaffirmed its financial guidance for the near and medium term, projecting a consistent revenue increase and improved gross margins. The company’s differentiated product offerings and strategic initiatives to enhance gross margin, despite certain challenges, further solidify its competitive position in the market. Mikson believes that the current stock price does not fully reflect the company’s long-term growth potential, making it an attractive investment opportunity at this time.
In another report released today, Barclays also maintained a Buy rating on the stock with a £1.60 price target.
Based on the recent corporate insider activity of 20 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ONT in relation to earlier this year.